Verona Pharma Announces December 2024 Investor Conference Participation
19. November 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma to Present at Jefferies London Healthcare Conference
05. November 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
04. November 2024 02:00 ET
|
Verona Pharma plc
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled...
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
21. Oktober 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third...
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
30. September 2024 02:00 ET
|
Verona Pharma plc
Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
05. September 2024 02:00 ET
|
Verona Pharma plc
Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08. August 2024 02:00 ET
|
Verona Pharma plc
OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST ...
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
30. Juli 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
25. Juli 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second...
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
26. Juni 2024 16:57 ET
|
Verona Pharma plc
Verona Pharma announces the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD in adult patients.